# Vonoprazan Hp Dual or Triple Eradication Regimes

> **NCT05345210** · PHASE4 · UNKNOWN · sponsor: **Xijing Hospital of Digestive Diseases** · enrollment: 500 (estimated)

## Conditions studied

- Helicobacter Pylori

## Interventions

- **DRUG:** Vonoprazan Fumarate+Amoxycillin+Clarithromycin 14days (VAC14)
- **DRUG:** Vonoprazan Fumarate+Amoxycillin 14days (VA14)
- **DRUG:** Vonoprazan Fumarate+Amoxycillin 7days (VA7)
- **DRUG:** Vonoprazan Fumarate+Tetracycline+Furazolidone 14days (VTF14)
- **DRUG:** Vonoprazan Fumarate+Tetracycline+Furazolidone 7days (VTF7)

## Key facts

- **NCT ID:** NCT05345210
- **Lead sponsor:** Xijing Hospital of Digestive Diseases
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-25
- **Primary completion:** 2023-02-28
- **Final completion:** 2023-03-31
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2022-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05345210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05345210, "Vonoprazan Hp Dual or Triple Eradication Regimes". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05345210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*